Department of Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Circulation. 2013 Jul 23;128(4):360-4. doi: 10.1161/CIRCULATIONAHA.113.001875. Epub 2013 Jun 14.
Physicians reverse patients' warfarin anticoagulation with frozen plasma or prothrombin complex concentrate. Our objective was to determine adverse event frequency after urgent reversal with frozen plasma versus the prothrombin complex concentrate Octaplex.
This natural before-after retrospective cohort study in 2 tertiary care emergency departments compared anticoagulation reversal with frozen plasma (September 2006-August 2008) and with Octaplex (September 2008-August 2010), without other system changes. We included adult patients on warfarin with an international normalized ratio ≥1.5 who received frozen plasma or Octaplex. Our primary outcome was serious adverse events (death, ischemic stroke, myocardial infarction, heart failure, venous thromboembolism, or peripheral arterial thromboembolism) within 7 days. Secondary outcomes included time to international normalized ratio reversal, hospital length of stay, and red blood cells transfused within 48 hours. We included 149 patients receiving frozen plasma and 165 receiving Octaplex. The incidence of serious adverse events for the frozen plasma group was 19.5% compared with 9.7% for the Octaplex group (P=0.014; relative risk, 2.0; 95% confidence interval, 1.1-3.5). This remained significant after adjustment for baseline history and reason for treatment (P=0.038; adjusted relative risk, 1.85; 95% confidence interval, 1.03-3.3) in multivariable regression analysis. Median international normalized ratio reversal was 11.8 hours with frozen plasma and 5.7 hours with Octaplex (P<0.0001). Mean red cell transfusion was 3.2 with frozen plasma and 1.4 with Octaplex (P<0.0001).
Octaplex for urgent reversal of warfarin resulted in faster reversal and lower red cell transfusion requirement with fewer adverse events than frozen plasma.
医生使用冷冻血浆或凝血酶原复合物浓缩物逆转患者的华法林抗凝作用。我们的目的是确定紧急逆转后使用冷冻血浆与凝血酶原复合物浓缩物 Octaplex 的不良事件发生率。
这项在两个三级保健急诊部门进行的自然前后回顾性队列研究比较了使用冷冻血浆(2006 年 9 月至 2008 年 8 月)和 Octaplex(2008 年 9 月至 2010 年 8 月)进行抗凝逆转的情况,期间没有其他系统变化。我们纳入了国际标准化比值(INR)≥1.5 的接受华法林治疗的成年患者,这些患者接受了冷冻血浆或 Octaplex。我们的主要结局是 7 天内出现严重不良事件(死亡、缺血性卒中、心肌梗死、心力衰竭、静脉血栓栓塞或外周动脉血栓栓塞)。次要结局包括 INR 逆转时间、住院时间和 48 小时内输注的红细胞量。我们纳入了 149 名接受冷冻血浆的患者和 165 名接受 Octaplex 的患者。冷冻血浆组的严重不良事件发生率为 19.5%,而 Octaplex 组为 9.7%(P=0.014;相对风险,2.0;95%置信区间,1.1-3.5)。在校正基线病史和治疗原因后,这一结果仍然显著(P=0.038;调整后的相对风险,1.85;95%置信区间,1.03-3.3)。多变量回归分析。冷冻血浆的 INR 中位逆转时间为 11.8 小时,Octaplex 的 INR 中位逆转时间为 5.7 小时(P<0.0001)。冷冻血浆的平均红细胞输注量为 3.2,而 Octaplex 的平均红细胞输注量为 1.4(P<0.0001)。
与冷冻血浆相比,Octaplex 用于华法林紧急逆转可更快逆转,红细胞输注需求更低,不良事件更少。